1 The EIC Accelerator Project
EIC Accelerator Program: An Overview
The EIC Accelerator program, part of the European Innovation Council (EIC), aims to support small and medium-sized enterprises (SMEs) and startups with high-risk, high-potential innovations. The program provides a blended finance solution combining grants and equity investments to help companies scale their businesses, particularly in the DeepTech sector. The EIC Accelerator focuses on fostering innovation that can lead to significant technological advancements and societal benefits.
Funding Structure
The EIC Accelerator offers funding in two main forms: grants and equity investments.
Purpose and Impact
The primary purpose of the EIC Accelerator is to enhance the European startup ecosystem, particularly in the DeepTech space, where innovative solutions often require substantial upfront investment. By offering blended finance, the EIC Accelerator mitigates the financial risks associated with early-stage innovation. This support enables companies to attract further investment from private sectors, thereby increasing their chances of success in a competitive market.
The EIC Accelerator plays a crucial role in helping startups and SMEs transition from the research and development phase to commercial viability. By providing both financial resources and mentorship, the program boosts the growth potential of innovative companies, encouraging them to expand their operations and reach.
Case Study: Op2Lysis and the OP2DRAIN Project
Company Overview: Op2Lysis, based in France, is a pioneering company focusing on innovative medical treatments. The company has recently gained recognition for its groundbreaking project, OP2DRAIN, which aims to deliver the first medical treatment specifically designed for patients suffering from hemorrhagic strokes.
Project Description: The OP2DRAIN project is dedicated to developing a novel therapeutic approach for the management of hemorrhagic strokes, a severe medical condition characterized by bleeding in the brain. This project is pivotal as it addresses a critical gap in current medical treatments for this condition, which can lead to severe neurological impairments or even death.
Technology Background: The underlying technology for OP2DRAIN is based on advanced biopharmaceutical techniques that focus on the selective targeting of hemorrhagic tissues. The treatment aims to enhance the body's natural mechanisms for coagulation and repair, thereby reducing the damage caused by bleeding in the brain. By utilizing innovative drug delivery systems and molecular biology techniques, Op2Lysis seeks to create a therapeutic solution that is both effective and minimally invasive.
Funding and Development Timeline
Op2Lysis submitted its Step 2 proposal for the EIC Accelerator on October 6, 2021. Following a rigorous evaluation process, the company successfully progressed to the Step 3 interview, where it was awarded funding to support the OP2DRAIN project. This funding will enable Op2Lysis to further its research, conduct clinical trials, and ultimately bring its innovative treatment to market.
Conclusion
The EIC Accelerator program serves as a vital enabler for companies like Op2Lysis, fostering innovation in critical sectors such as healthcare. Through its blended finance model, the program not only provides essential funding but also helps companies scale their operations and attract private investment, ultimately contributing to the advancement of technology and the improvement of societal health outcomes.
2 The Funding Rounds
Op2Lysis, a French biotechnology company specializing in innovative medicines for cerebrovascular thrombotic diseases, won the European Innovation Council (EIC) Accelerator funding in the October 2021 cut-off round. Since receiving this prestigious support, here is a detailed overview of their financing history, funding rounds, investor information, and related events:Financing Raised and Funding Rounds
- Op2Lysis has conducted several rounds of fundraising since its inception to develop its lead product O2L-001 and build a competitive team around its NANOp2Lysis® technology platform. Their financing strategy leverages both grants and equity investments as part of their growth plan.
- The key milestone was winning the EIC Accelerator grant in October 2021 (cut-off date: 6th October 2021), which provided blended finance combining EU grants with co-investments through the EIC Fund—a combination designed to catalyze additional private investment towards breakthrough innovations.
Timing and Amount of Funding Rounds
- While exact amounts from private rounds before or after the EIC award are not publicly detailed, it is established that Op2Lysis secured multiple funding injections prior to advancing O2L-001 into clinical development phases.
- The EIC Accelerator program awarded substantial financial support starting from late 2021 onward. This typically includes up to several million euros split between non-dilutive grants and equity investments via the EIC Fund; such funds facilitate regulatory development plans validated in September 2021 with EMA pre-IND consultation.
Investor Information
- The primary investor linked directly to their recent funding success is the European Innovation Council via its dedicated investment arm—the EIC Fund—which acts as Europe’s largest deep-tech investor providing both capital injection and validation that attracts further investors.
- Additional private investors have been implied by references to co-investments attracted due to this public backing but specific venture capital firms or angel investors have not been explicitly named in available sources.
Company Valuation
Funding or Exit Events
- There are no records indicating any exit events such as IPOs or acquisitions involving Op2Lysis since their receipt of EIC funding.
- Instead, they remain focused on advancing clinical trials (e.g., MisTIE trials referenced) for hemorrhagic stroke treatment using O2L001 underpinned by robust translational data showing potential efficacy benefits over current thrombolytic agents.
Summary Table of Known Details on Op2Lysis Financing Post-EIC Award
| Aspect | Detail |
|---|---|
| Country | France |
| Key Product | O2L-001 (treatment for intracerebral hemorrhage) |
| Technology Platform | NANOp2Lysis® & OptPA thrombolytic agent |
| Major Funding Event | Winner of Oct 2021 EIC Accelerator grant + equity co-investment |
| Investors | European Innovation Council / EIC Fund |
| Funding Type | Blended finance: EU grant + equity |
| Clinical Milestones | EMA preIND consultation Sep 2021; ongoing MisTIE clinical trials |
| Company Valuation | Not disclosed publicly but inferred significant due to selective EU innovation award |
| Exits | None reported |
In conclusion, since winning the highly competitive October 2021 round of the European Innovation Council’s Accelerator program on October 6th, Op2Lysis has successfully leveraged this mixed public-private financing model to advance towards critical clinical milestones with their groundbreaking therapy targeting hemorrhagic stroke. Further private investment details remain confidential but involvement with Europe’s largest deep-tech fund underscores strong confidence in their innovation potential.
Sources: - EIC press release - Op2lysis laureate Oct 2021
-European Commission – Latest news about funded companies -La French Tech – Company profile -Op²lysis official website About Us section3 The Press Releases
Op2Lysis, a French biotechnology company, has made significant progress and developments since winning the EIC Accelerator funding in October 2021. The company focuses on innovative medicines to lyse hematoma and blood clots formed during thrombosis in the brain, particularly targeting hemorrhagic stroke, an area with unmet medical needs.Key Technologies and Products
Company Background & Development Milestones
Founded through collaboration between experts Christophe Gaudin (cardiovascular development) and Jérôme Parcq (OptPA inventor), Op2Lysis has raised multiple rounds of funding focusing initially on O2L-001 prototypes demonstrating high thrombolytic efficacy in translational models. To support regulatory development efforts across borders, they established a sister company Op2Lysis Development SA based in Liège, Belgium.
Their strategy leverages documented clinical proof-of-concept data underpinning their drug candidates’ potential impact on cerebrovascular diseases.
Partnerships & Recognition
- Op2Lysis was named laureate of several prestigious programs including NETVA Boston, i-LAB competitions as well as receiving SME Instrument Phase 1 “Seal Of Excellence” recognition prior to their EIC Accelerator award.
- Supported by EIT Health’s Virtual Care Observatory & Ecosystem (VCoE), Op2Lysis has been nominated for awards like Prix Galien highlighting its innovation potential within European healthcare startups focused on transformative therapies for stroke treatment.
Recent Updates & Public Communications
No specific recent press releases or detailed blog posts were found directly posted on their website or social media channels beyond foundational corporate information describing their technology platforms and pipeline products. However:
- Their website serves as a key source outlining product details like O2L-001's mechanism addressing unmet clinical needs around hemorrhagic stroke treatment using advanced thrombolytic agents combined with nanoparticle delivery systems.
- Mentioned involvement with ecosystem partners such as EIT Health suggests ongoing collaborative efforts facilitating access to funding networks, expert guidance, regulatory pathways support likely enhancing their clinical development trajectory post-EIC Accelerator award.
Patents & Technology Advancements
While explicit patent filings are not publicly detailed in available sources:
- The proprietary nature of OptPA as a genetically engineered improved tPA variant strongly indicates intellectual property protection.
- NANOp2Lysis® platform represents a unique drug delivery system likely covered under patent applications given its described novelty.
Advances also include extended-release formulations aimed at improving patient compliance through less frequent dosing schedules—a technological enhancement relevant for chronic cerebrovascular disease treatments.
Summary Table: Opportunities Enabled Post-EIC Accelerator Funding
| Aspect | Details |
|---|---|
| Technology | NANOp2lysis® nanocarrier platform; OptPA engineered safer thrombolytic agent |
| Lead Product | O₂L‑001 - targeted hematoma lysis therapy for hemorrhagic stroke |
| Clinical Focus | Cerebrovascular diseases; specifically intracerebral hemorrhage |
| Company Structure | Two entities: Op₂lysis SAS (France) + Development SA (Belgium) |
| Recognitions | SME Instrument Seal Of Excellence; NETVA Boston laureate; i-LAB winner |
| Ecosystem Support | Supported by EIT Health VCoE; Prix Galien nomination |
| Advances | Extended-release formulation; improved safety profile |
In conclusion, since winning the EIC Accelerator funding after submitting its Step 2 proposal in October 2021, Op₂lysis has continued advancing its innovative therapeutic approach addressing hemorrhagic stroke via cutting-edge nanomedicine technologies incorporating safer thrombolytics like OptPA. Its strategic partnerships within European health innovation networks further bolster its capacity toward successful clinical translation.
Sources
Op₂lysis Official Website The Company - About Us Page Dealroom.co Profile La French Tech Profile Craft.co Company Overview EIT Health News Article - Prix Galien Nomination4 The Technology Advancements
Op2Lysis, a French biotechnology company, focuses on developing innovative medicines to lyse hematomas and blood clots formed during brain thrombosis, particularly targeting hemorrhagic stroke. Their core technology platform is NANOp2Lysis®, which aims to enhance the efficacy and safety of thrombolytic agents for neurovascular diseases.Current Capabilities
- NANOp2Lysis® Technology: A disruptive drug delivery platform designed to improve the action of thrombolytic agents by enabling targeted and controlled release. This technology underpins their product portfolio aimed at treating cerebrovascular thrombotic diseases.
- OptPA (Optimized tPA): A novel thrombolytic agent engineered from tissue plasminogen activator (tPA) with an improved safety profile that reduces pro-bleeding risk and avoids neurotoxicity, enhancing treatment safety compared to standard therapies.
- O2L-001: The first product developed on the NANOp2Lysis® platform specifically for hemorrhagic stroke treatment. It is designed for rapid and safe removal of intracerebral hematomas via localized administration coupled with minimally invasive surgical techniques. It aims to reduce disability and mortality in acute phases of hemorrhagic strokes.
Advancements Since Receiving EIC Accelerator Funding in October 2021
Since Op2Lysis received EIC Accelerator funding in October 2021:
- The company has progressed significantly with its O2L-001 program, producing initial batches and prototypes demonstrating high thrombolytic efficacy in translational models relevant to hemorrhagic stroke.
- They have actively advanced their clinical development plans aiming to demonstrate clinical efficacy and safety sufficient for entering advanced development phases as early as 2023 according to consulting reports related to drug development programs involving Op2Lysis.
- In early 2024 retrospectives shared by Op2Lysis highlight ongoing live progress bringing new hope for hemorrhagic stroke patients daily, suggesting active engagement towards clinical translation or preparatory work towards trials or market demonstrations.
Technology Improvements & New Features
The key improvements revolve around:
- Enhanced formulation through their NANOp2Lysis® platform allowing extended-release profiles that reduce dosing frequency while maintaining therapeutic effectiveness.
- Optimization of OptPA as a safer thrombolytic agent avoiding neurotoxicity issues traditionally associated with tPA-based treatments.
These improvements focus on increasing both safety and ease of use alongside therapeutic potency — critical factors for treating delicate brain conditions like intracerebral hematoma after strokes.
Demonstrations in Market or Clinical Settings
While there is no direct public record yet confirming completion or publication of late-stage clinical trials:
- Op2Lysis has been actively engaged in preclinical proof-of-concept studies using translational models showing promising results supporting initiation into clinical phases shortly after funding receipt.
- The company’s strategy involves minimally invasive surgical adjuncts which may be tested initially via demonstrators or pilot collaborations within specialized hospital settings before full-scale trials.
The available evidence points towards preparations or possibly early-phase human studies designed but not yet publicly detailed extensively beyond preclinical data summaries as of early 2025.
Intellectual Property & Scientific Publications
There are no specific new patents disclosed publicly since the EIC funding award visible from current open databases. Similarly:
- No newly published scientific articles directly attributed solely to Op2Lysis post-funding have been identified; however,
- Related academic research involving partners linked through collaborations continues advancing knowledge on cerebral ischemia/thrombolytics potentially feeding into Op2lysis’s pipeline indirectly.
No whitepapers explicitly authored by them are found online currently either but ongoing R&D efforts are suggested by their public communications describing product prototypes and translational research outcomes since late 2021 .
Summary Table: Post-EIC Funding Status (Since Oct 2021)
| Aspect | Status / Details |
|---|---|
| Core Technology | NANOp2lysis® platform delivering optimized thrombolytics |
| Lead Product | O2L‑001 – targeted hematoma lysis therapy |
| Technological Advances | Extended-release formulation; optimized OptPA reducing bleeding risk |
| Clinical Progress | Preclinical proof-of-concept completed; preparing/entering advanced development phase |
| Market Demonstrations | Preparatory steps toward demos/pilots implied; no confirmed commercial launches yet |
| Patents/Publications | No new public patents/scientific publications identified post-funding |
| Collaborations | Academic partnerships continue supporting R&D |
In conclusion, since receiving EIC Accelerator funding on October 6, 2021, Op2lysis has made important strides refining its proprietary NANOplysis® technology along with its lead candidate O₂l‑001 aimed at hemorrhagic stroke treatment. They have demonstrated strong preclinical efficacy data supporting advancement toward clinical trial stages but have not yet publicly released details about large-scale human studies or new patent filings post-funding. Their ongoing efforts suggest readiness for deeper clinical validation potentially leading up to market introduction pending regulatory approvals within the near future.
Sources
Op2lysis Official Website - About & Technology Retrospective - 2023 Update from Op₂lysis Academic Article about O₂l‑001 Voisin Consulting Drug Development Program Overview BrainWeek Feature on Startups including Op₂lysis Company History & Strategy – op₂lysis About Us page TREAT Neurolab Research Collaboration Reference Synapse Patent & Pipeline Data Overview5 The Partnerships and Customers
Since receiving the EIC Accelerator funding in October 2021, Op2Lysis, a French biotechnology company specializing in innovative treatments for hemorrhagic stroke through its NANOp2Lysis® technology and the optimized thrombolytic agent OptPA, has been progressing its development and market positioning primarily around its lead product O2L-001.Partnerships and Customers
No explicit new partnerships or customer names have been publicly disclosed since their EIC Accelerator award. However, Op2Lysis operates within a network of biopharmaceutical collaborators typical for biotech innovators developing advanced therapeutics. Their technology platform NANOp2Lysis® focuses on drug delivery advancement to lyse hematomas safely and effectively. This innovative approach likely involves collaborations with research institutions, clinical partners conducting trials, and manufacturing specialists.
In terms of manufacturing partnerships or service providers supporting scale-up or process development aspects common to biotech companies at this stage, entities like GTP Bioways (recognized in industry for GMP manufacturing of nanodrugs) are examples of suppliers commonly engaged by companies like Op2Lysis but no direct link is confirmed from available data.
Nature of Relationships and Purpose
The purpose behind any partnerships would be to:
- Advance clinical development by enabling rigorous trials demonstrating safety and efficacy of O2L-001.
- Scale up production capabilities ensuring GMP compliance.
- Facilitate regulatory approval pathways across Europe and globally.
- Support further technological innovation enhancing nanoparticle-based thrombolytic delivery.
These efforts align with Op2Lysis’s mission to address unmet needs in hemorrhagic stroke treatment through safer clot lysis that reduces neurotoxicity risks compared to existing therapies.
Market Positioning Impact
Any newly formed relationships would position Op2Lysis as an emerging player focused on breakthrough therapies for cerebral thrombosis-related conditions by leveraging nanotechnology-enhanced pharmaceuticals. This niche focus addresses significant unmet medical needs where current options are limited or risky.
Strategic collaborations could elevate their competitive stance against other firms working on stroke treatment solutions by accelerating time-to-market for O2L-001 while validating the NANOp2Lysis® platform’s broader applicability.
Technology Advancements & Scaling Benefits
Partnerships with:
- Clinical trial centers enable robust validation critical for regulatory acceptance.
- Manufacturing organizations enhance capacity enabling transition from R&D-scale lab batches to commercial-scale production.
- Research institutions provide ongoing innovation input improving drug delivery efficiency or expanding indications beyond hemorrhagic strokes.
Such relationships help reduce risks associated with scale-up challenges while driving improvements in product safety profiles — key factors underpinning successful commercialization within pharmaceutical markets.
In summary, although specific names of new partners or customers post-EIC funding are not publicly detailed at present, it is clear that Op2Lysis’s strategic focus lies in forming collaborations that advance clinical development, manufacturing scale-up, regulatory approval processes, and technological innovation. These alliances will strengthen their market position as an innovator offering safer thrombolytic solutions addressing critical gaps in stroke care. The anticipated impact includes enhanced ability to bring O2L-001 efficiently from bench through clinic into patient use while expanding NANOp2lysis® platform applications over time.
Sources:
Op2lysis company website
GTP Bioways references
New Approaches in Nanomedicine - PMC
6 The Hiring and Company Growth
Op2Lysis, a French biotechnology company founded in 2016 and headquartered in Boulogne-Billancourt, focuses on developing innovative medicines to lyse hematoma and blood clots formed during thrombosis in the brain. Since winning the EIC Accelerator funding with their Step 2 proposal submitted on October 6, 2021, Op2Lysis has been advancing its flagship product O2L-001 based on their NANOp2Lysis® platform and optimized thrombolytic agent OptPA.Hiring and Team Growth
- Current Headcount/Team Size: Specific current headcount details for Op2Lysis are not publicly disclosed as of now. However, information suggests that since its inception, the company has been building a competitive team to develop its products and advance regulatory processes through its sister company Op2Lysis Development SA in Liege (Belgium). The team includes scientific researchers from multiple domains such as hematology, neuroscience, molecular biology, and drug development.
- Recent Team Additions: While direct recent hires at Op2Lysis are not explicitly listed online, affiliated research associates who have collaborated with or contributed to projects linked with Op2Lysis include professionals like Estelle Louet (joined 2022), Agnes Adler (joined 2023), Sara Conde (joined 2024), and Sergio de Hita Román (joined 2025) working primarily through related consulting firms or academic partnerships supporting translational biomedical research relevant to Op2Lysis’s focus.
- Growth Since EIC Funding: After receiving the European Innovation Council Accelerator grant post October 2021 submission date, it is reasonable to infer strategic growth both in R&D capabilities and regulatory development functions via their Belgian sister entity. This funding likely enabled scaling up operations including prototyping O2L-001 batches demonstrating efficacy on translational models. No precise numerical growth figures are public.
Hiring Status & Key Positions
Impact of New Team Members
Newly added team members—especially those with expertise in neurovascular diseases, thrombolytics research, preclinical studies—and those facilitating regulatory compliance will be instrumental for:
- Accelerating clinical trials for O₂L-001.
- Ensuring robust safety profiling of OptPA.
- Expanding lab capabilities around NANOp₂lysis® platform technology.
This enhanced human capital supports scaling up from prototype proof-of-concept stages toward commercialization readiness addressing unmet needs of hemorrhagic stroke treatment safely reducing mortality/morbidity.
Management Changes
No major changes concerning management or founding teams have been reported publicly since inception. The founders Christophe Gaudin (cardiovascular drug expert) and Jérôme Parcq (Inventor of OptPA) remain central figures driving strategy alongside scientific advisors like Dr. Cécile Oury (hematologist) and Dr. Denis Vivien (neuroscientist).
In summary:
| Aspect | Information Available |
|---|---|
| Current Headcount | Not publicly disclosed |
| Recent Hiring | Collaborations indicate additions mainly via related consultants/researchers |
| Growth Post-EIC Funding | Enhanced R&D & regulatory teams; scale-up inferred but no exact numbers |
| Currently Hiring | No explicit info; likely hiring biomedical/scientific/regulatory roles |
| Key Positions Recently Filled | Research associates specialized in neurovascular/thrombolytic fields |
| Impact of New Hires | Enable clinical/commercial scale-up; improve product safety & efficacy |
| Management Changes | No major changes reported since founding |
Op²lysis continues focused growth leveraging EIC funds by strengthening multidisciplinary expertise essential for advancing breakthrough hemorrhagic stroke treatments toward market availability.
Sources: - Op²lysis Official Website - About Us
- Op²lysis Product Overview
- Dealroom - Op²lysis Profile
- Craft.co Company Profile
- Research Associates Connected with Op²lysis Projects
7 The Media Features and Publications
Overview of Op2Lysis
Op2Lysis is a French biotechnology company that focuses on developing innovative medicines to lyse hematoma and blood clots formed during thrombosis in the brain, particularly for treating hemorrhagic stroke. The company's mission is to improve the management and treatment of cerebrovascular thrombotic diseases, leveraging its NANOp2Lysis technology and an optimized version of tissue plasminogen activator (tPA), known as OptPA.
Media Features and Publications
While specific media features or detailed publications mentioning Op2Lysis could not be identified in the search results, it is known that the company has been active in developing groundbreaking treatments like O2L-001, which is designed to effectively and safely evacuate intracerebral hemorrhages. O2L-001 has been featured in scientific discussions as a potential breakthrough in treating hemorrhagic stroke, showcasing its efficacy in lysis and reducing risks compared to traditional tPA treatments.
Podcasts or Interviews
There are no specific details available regarding podcasts or interviews conducted by the team of Op2Lysis in the provided search results.
Conference and Fair Visits
Op2Lysis likely participates in healthcare and biotechnology conferences, such as those organized by platforms like BioFIT, which connects early-stage innovations in life sciences with potential investors and partners. However, specific details about Op2Lysis's participation in these events are not available in the current search results.
Involvement in Events
Given Op2Lysis's focus on developing innovative treatments for cerebrovascular diseases, the company would likely engage in various life sciences events aimed at advancing medical research and technology. Their participation in such events aligns with their mission to improve stroke treatment and management.
EIC Accelerator Funding
Op2Lysis received the EIC Accelerator funding in October 2021. This funding signifies the company's potential to bring impactful solutions to the field of healthcare, particularly in addressing unmet medical needs related to stroke and thrombosis.
Sources: - Op2Lysis | Innovative treatment for hemorrhagic stroke
- O2L-001, an innovative thrombolytic to evacuate intracerebral
- Retrospective - 2023 in a nutshell - Op2Lysis
- O2L-001, an innovative thrombolytic to evacuate intracerebral
- The Company - Op2Lysis
- PROGRAMME - BioFIT Event
Do you need EIC Accelerator support?
Here is a list of the key service options for the EIC Accelerator:
Full Writing Service
All proposal sections are written by Stephan Segler, PhD.
Advisory Service
You write in-house but receive 1-on-1 support, templates, instructions, and reviews of all documents.
AI Writer & Training
A high-quality AI writer for EIC Accelerator Step 1 and a comprehensive Training program for Steps 1 and 2 including all templates and instructions.